News articles about Inovalon (NASDAQ:INOV) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Inovalon earned a daily sentiment score of 0.05 on Accern’s scale. Accern also gave press coverage about the technology company an impact score of 45.630292852126 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
A number of analysts have recently issued reports on INOV shares. Zacks Investment Research upgraded shares of Inovalon from a “sell” rating to a “hold” rating in a report on Saturday, February 24th. ValuEngine downgraded shares of Inovalon from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. Morgan Stanley downgraded shares of Inovalon from an “equal weight” rating to an “underweight” rating and set a $10.00 price target for the company. in a report on Wednesday, March 14th. TheStreet upgraded shares of Inovalon from a “d+” rating to a “c” rating in a report on Thursday, March 15th. Finally, BidaskClub upgraded shares of Inovalon from a “strong sell” rating to a “sell” rating in a report on Tuesday, April 24th. Three investment analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. Inovalon currently has a consensus rating of “Hold” and a consensus price target of $12.00.
Inovalon traded up $0.05, hitting $9.95, during trading on Friday, Marketbeat Ratings reports. The company had a trading volume of 927,110 shares, compared to its average volume of 627,899. Inovalon has a 1-year low of $8.90 and a 1-year high of $17.80. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.48 and a current ratio of 4.48. The company has a market capitalization of $1.51 billion, a PE ratio of 43.26, a price-to-earnings-growth ratio of 3.65 and a beta of 1.02.
Inovalon (NASDAQ:INOV) last posted its earnings results on Tuesday, May 8th. The technology company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by ($0.10). Inovalon had a net margin of 3.20% and a return on equity of 2.50%. The company had revenue of $92.76 million during the quarter, compared to analyst estimates of $107.76 million. During the same quarter last year, the business posted $0.07 EPS. The firm’s revenue for the quarter was down 14.4% on a year-over-year basis. equities research analysts forecast that Inovalon will post 0.19 earnings per share for the current year.
In related news, CEO Keith R. Dunleavy bought 36,753 shares of the company’s stock in a transaction that occurred on Monday, May 14th. The stock was purchased at an average price of $9.97 per share, for a total transaction of $366,427.41. Following the acquisition, the chief executive officer now owns 318,753 shares of the company’s stock, valued at $3,177,967.41. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Lee D. Roberts bought 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $10.54 per share, with a total value of $105,400.00. Following the acquisition, the director now directly owns 91,804 shares in the company, valued at approximately $967,614.16. The disclosure for this purchase can be found here. Insiders purchased a total of 164,753 shares of company stock valued at $1,641,207 in the last quarter. 50.93% of the stock is owned by insiders.
Inovalon Company Profile
Inovalon Holdings, Inc, a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company's platform enables the assessment and enhancement of clinical and quality outcomes and financial performance.
Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.